To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
VC-backed Gyroscope postpones IPO plans
London-based Gyroscope Therapeutics, a gene therapy company focused on treating eye diseases, has postponed its IPO plans, citing market conditions as the reason.
